Early detection is the key to successful treatment and survival rates.
With advances in colon cancer screening tests, such as Cologuard, which allows you to collect a stool sample in the privacy of your own home, screening for colon cancer has become a relatively simple, noninvasive process.
The National Cancer Institute estimates 4.7 percent of men and women will be diagnosed with colon or rectal cancer at some point in their lifetime. The good news is that colon cancer rates have been steadily dropping thanks to remarkable advances in noninvasive colon cancer screening techniques and treatments.
Five-year Colorectal Cancer-specific Survival by Stage and Race/Ethnicity, 2003-2009
Local: Cancers that have grown into the wall of the colon or rectum, but have not extended through the wall to invade nearby tissues.
Regional: Cancers that have spread through the wall of the colon or rectum and have invaded nearby tissues, or that have spread to nearby lymph nodes.
Distant: Cancers that have spread to other parts of the body, such as the liver or lung.
Monday-Friday, 8:00am-5:00pm PST
Cologuard is an easy to use, noninvasive colon cancer screening test based on the latest advances in stool DNA science. It can be used by men and women 50 years of age and older who are at average risk for colon cancer.
If you are over the age of 50 and have a typical average risk of developing colon cancer, a simple, noninvasive test may mean the difference between early diagnosis and successful treatment or loss of life.
More information is available on the Cologuard website or call us at 888.670.2231 to speak to a health care coordinator.
Individuals with the following conditions are considered at higher risk of developing colon cancer.
- A family history of colon cancer and colon polyps
- Being over the age of 50
- A personal history of colorectal polyps
- A diet low in fiber and high in fat
- A sedentary lifestyle
- Alcohol and tobacco use
- Diabetes or insulin resistance
Cologuard was not clinically evaluated for the following types of patients and thus they are not eligible candidates for the Cologuard test:
- Patients with a history of colorectal cancer, adenomas, or other related cancers
- Patients who have had a positive result from another colorectal cancer screening method within the last 6 months
- Patients who have been diagnosed with conditions associated with high risk for colorectal cancer. These conditions include but are not limited to:
- Inflammatory Bowel Disease (IBD)
- Chronic ulcerative colitis (CUC)
- Crohn’s disease or Familial adenomatous polyposis (FAP)
- Family history of colorectal cancer
According to the Colon Cancer Alliance, “Screening is the number one way you can reduce your risk of colon cancer. Despite its high incidence, colon cancer is unique in that it is one of the most preventable and, if found early, most treatable forms of cancer.”
Precancerous polyps and colorectal cancer (cancer of the colon or rectum) do not always cause symptoms and this is why it is so important to take advantage of early screening opportunities.
According to the Centers for Disease Control and Prevention, “Among cancers that affect both men and women, colorectal cancer is the second leading cause of cancer deaths in the United States. Every year, about 140,000 Americans are diagnosed with colorectal cancer, and more than 50,000 people die from it.”
The American Cancer Society’s estimates for the number of colorectal cancer cases in the United States for 2015 are:
- 93,090 new cases of colon cancer
- 39,610 new cases of rectal cancer
Cases that occur in people 50 or older
Lifetime risk of developing colorectal cancer
Cases arise in the colon